Patient Surveys

Take The Survey Now

Click Image to download

Welcome to the 12th year of the Kidney Cancer UK Patient Survey, the only survey dedicated solely to UK kidney cancer patients. We greatly appreciate your time in completing this survey. Your insights into the wide range of life and health experiences of those affected by kidney cancer are vital. The information you share will help us drive meaningful improvements for patients across the UK. At the same time, Kidney Cancer UK will continue to use this knowledge to identify how best to support you throughout your kidney cancer pathway.

If you would like to download a paper copy of the survey, please CLICK HERE. A  new page will open with the PDF version to download, print out and return via FREEPOST, writing just FREEPOST KIDNEY CANCER UK on the envelope.

If you would like us to send you a paper copy of the survey through the post, to complete at home, with a free return envelope using FREEPOST, please CLICK HERE

If, for any reason, you are unable to complete this survey online, contact our office on 01223 870008 and a member of our team will be pleased to complete the survey over the telephone with you.

If you would like to read any of our previous surveys dating back to 2013, please click HERE

If you would like to donate and help us in our work of supporting and informing kidney cancer patients across the UK, please click here.

Publication of this survey

The results of this survey will be published on 2nd February 2026. The results will be used to highlight the challenges faced by kidney cancer patients, as well as the effectiveness of diagnosis and treatments. Results from the survey will form part of our 11th Kidney Cancer Awareness Week 2026, which will run from February 2nd to 6th, culminating in Green Friday on February 6th, 2026.

Please save the date and help us raise awareness across the UK as one community.

Thank you for your support.

Note: This survey is supported with financial support from Boston Scientific, Ipsen, Merck, MSD, Pfizer and Telix Pharmaceuticals. Funders had no input into the questions, structure, analysis or content of the survey.